Aura Biosciences Inc (AURA)vsRevolution Medicines Inc (RVMD)
AURA
Aura Biosciences Inc
$7.01
+0.21%
HEALTHCARE · Cap: $725.41M
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. AURA earns a higher WallStSmart Score of 28/100 (F).
AURA
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AURA
The strongest argument for AURA centers on Debt/Equity, Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : AURA
The primary concerns for AURA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
AURA is growing revenue faster at 0.0% — sustainability is the question.
AURA generates stronger free cash flow (-32M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AURA scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aura Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The company’s lead investigational therapy, AU-011, specifically targets ocular cancer cells, striving to eliminate tumors while safeguarding surrounding healthy tissue—demonstrating a commitment to precision oncology. With a robust pipeline designed to address critical unmet needs in cancer care and a highly experienced management team, Aura is strategically positioned to make significant advancements in the oncology market. Furthermore, its collaborative approach enhances innovation potential and aligns with the sector's growing demand for targeted therapies.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?